EFTR News and Press, eFFECTOR Therapeutics Inc. From 03/25/24

2024-03-25 18:04:15 ET More on eFFECTOR Therapeutics eFFECTOR Therapeutics announces $15M registered direct offering Seeking Alpha’s Quant Rating on eFFECTOR Therapeutics Read the full article on Seeking Alpha For further details see: eFFECTOR Ther...

Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination ...

Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...

SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...

2024-02-26 05:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that Steve Worland, Ph.D., pr...

2024-02-05 01:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced...

2024-01-25 08:31:21 ET More on eFFECTOR Therapeutics eFFECTOR updates Phase 1/2 data for breast cancer therapy eFFECTOR stock rises after FDA fast track status for breast cancer therapy Seeking Alpha’s Quant Rating on eFFECTOR Therapeutics Historical e...

2024-01-25 08:25:44 ET More on Pre-market losers & stocks. LG Display Co Ltd (LPL) Q4 2023 Earnings Call Transcript LG Display: It Is The Long-Term Picture That Is Giving People Pause Silo Pharma stock rises after inking exclusive license deal with Medspray Pharm...